title: Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats.
abstract: Exposure to severe stress leads to development of neuropsychiatric disorders, including depression and Post-Traumatic Stress Disorder (PTSD) in at-risk individuals. Neuropeptide Y (NPY) is associated with resilience or improved recovery. Therefore exogenous administration to the brain has therapeutic potential although peripheral administration can trigger undesirable side effects. Here, we established conditions with intranasal (IN) NPY infusion to rats to obtain CSF concentrations in the proposed anxiolytic range without significant change in plasma NPY. Rats were pretreated with IN NPY or vehicle before exposure to single prolonged stress (SPS) animal model of PTSD and compared to untreated controls. The IN NPY appeared to lessen the perceived severity of stress, as these animals displayed less time immobile in forced swim part of the SPS. Thirty minutes after SPS the elevation of plasma adrenocorticotropic hormone (ACTH) and corticosterone was not as pronounced in NPY-infused rats and the induction of tyrosine hydroxylase (TH) in locus coeruleus (LC) was attenuated. Seven days after SPS, they displayed lower depressive-like behavior on Forced Swim Test and reduced anxiety-like behavior on Elevated Plus Maze. The prolonged effect of SPS on Acoustic Startle Response was also lower in NPY-infused rats. Plasma ACTH, corticosterone, and hippocampal glucocorticoid receptor levels were significantly above controls only in the vehicle - but not IN NPY-treated group 1week after SPS. Baseline TH mRNA levels in LC did not differ among groups, but increased with forced swim in the vehicle - but not NPY-pretreated animals. Administration of IN NPY after exposure to SPS led to similar, but not identical, reduction in development of anxiety, depressive-like behavior and hyperarousal. The results show that single IN NPY can alter stress-triggered dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and activation of central noradrenergic activity. These findings provide proof of concept for potential of IN NPY for non-invasive prophylactic treatment or early intervention in response to traumatic stress.
authors: Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA.
authors: L I
authors: LI
authors: Serova
authors: A
authors: A
authors: Tillinger
authors: L G
authors: LG
authors: Alaluf
authors: M
authors: M
authors: Laukova
authors: K
authors: K
authors: Keegan
authors: E L
authors: EL
authors: Sabban
mesh_terms: D000281:Administration, Intranasal; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D015153:Blotting, Western; D003345:Corticosterone / Q000097:blood; D004195:Disease Models, Animal; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D008297:Male; D009478:Neuropeptide Y / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D013216:Reflex, Startle / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000209:etiology; D013315:Stress, Psychological / Q000150:complications*
chemical_list: D009478:Neuropeptide Y; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone